Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Two hundreds and ten women with premenstrual syndrome will be randomly divided into 3 equal
groups using computer generated random numbers. Group 1 will receive oral dienogest (visanne®
Bayer, Germany) 2mg for 14 days starting from the 15th day of menstruation, Group 2 will
receive fluoxetine (Prozac® Lilly, UK) 20mg and group 3 will receive an oral placebo foe 14
days starting from the 15th day of menstruation.